Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term safety and efficacy of PF-06835919 in hereditary fructose intolerance
2023-000033-33Phase 2Completed
- Sponsor
- Maastricht University
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of PF-06835919 in Fructosemia (HFI), sponsored by Maastricht University. Primary endpoints: Intestinal fructose tolerance, Hepatic fructose tolerance and 1 more. Started May 2023; status: completed.
02
Drugs
PF-06835919
03
Conditions
Fructosemia (HFI)
Beyond the preview
Go deeper on 2023-000033-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000033-33.